Literature DB >> 6439183

Comparison of the effects of molsidomine, nitroglycerin and isosorbide dinitrate on experimentally induced coronary artery thrombosis in the dog.

P A Martorana, B Kettenbach, H Göbel, R E Nitz.   

Abstract

Platelet activation and aggregation in the coronary circulation may be important in the pathogenesis of myocardial ischemia. Molsidomine (M), isosorbide dinitrate (ISDN) and nitroglycerin (NTG) have been found to inhibit platelet aggregation in vitro. In the present study, the activity of these compounds was investigated in a model of coronary artery thrombosis in vivo. Dogs were anesthetized, thoracotomized, and their heart was exposed. An electrode was inserted into the left circumflex coronary artery and set to rest on the intima. Electrical stimulation (9 V, 150 microA) lasted for 6 h. Compounds (each in 2 dose levels) were given as an i.v. infusion starting 30 min after the beginning of the stimulation and lasting for the duration of the experiment. All control (saline-treated) animals underwent thrombotic occlusion of the coronary artery as assessed by flow measurement. On the other hand, 2/8 dogs treated with the lower M dose and 4/8 dogs treated with the higher M dose did not have a coronary occlusion. Neither ISDN nor NTG, at both doses, prevented the coronary occlusion. In control animals thrombus wet weight was 74.43 +/- 11.25 mg. M reduced the thrombus weight in a dose-related manner, while ISDN (marginally) and NTG (significantly at the higher dose) increased this parameter. Following the coronary thrombosis, all control animals developed myocardial infarcts as assessed by the tetrazolium technique. Similarly all animals treated with ISDN and with NTG (at both doses) showed infarcts. However, 3/8 M-dogs did not have a myocardial infarction in the lower as well as in the higher dose groups. The hemodynamic changes induced by the 3 compounds were similar in magnitude. Thus M but not ISDN or NTG showed in this in-vivo study antithrombotic and consequently antiischemic activity.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6439183     DOI: 10.1007/bf01910479

Source DB:  PubMed          Journal:  Basic Res Cardiol        ISSN: 0300-8428            Impact factor:   17.165


  25 in total

1.  Note on an exact treatment of contingency, goodness of fit and other problems of significance.

Authors:  G H FREEMAN; J H HALTON
Journal:  Biometrika       Date:  1951-06       Impact factor: 2.445

2.  Inhibition of platelet aggregation and stimulation of guanylate cyclase by an antianginal agent molsidomine and its metabolites.

Authors:  M Nishikawa; M Kanamori; H Hidaka
Journal:  J Pharmacol Exp Ther       Date:  1982-01       Impact factor: 4.030

3.  Production of circulating platelet aggregates by exercise in coronary patients.

Authors:  A G Kumpuris; R J Luchi; C C Waddell; R R Miller
Journal:  Circulation       Date:  1980-01       Impact factor: 29.690

4.  Electrical induction of coronary artery thrombosis in the ambulatory canine: a model for in vivo evaluation of anti-thrombotic agents.

Authors:  J L Romson; D W Haack; B R Lucchesi
Journal:  Thromb Res       Date:  1980-03-15       Impact factor: 3.944

Review 5.  Role of blood platelets in coronary artery disease.

Authors:  J I Haft
Journal:  Am J Cardiol       Date:  1979-06       Impact factor: 2.778

6.  The beneficial effects of oral ibuprofen on coronary artery thrombosis and myocardial ischemia in the conscious dog.

Authors:  J L Romson; L R Bush; D W Haack; B R Lucchesi
Journal:  J Pharmacol Exp Ther       Date:  1980-10       Impact factor: 4.030

7.  The effects of oral nafazatrom (= BAY g 6575) on canine coronary artery thrombosis and myocardial ischemia.

Authors:  V B Fiedler
Journal:  Basic Res Cardiol       Date:  1983 May-Jun       Impact factor: 17.165

8.  The effects of molsidomine and its metabolite SIN-1 on coronary vessel tone, platelet aggregation, and eicosanoid formation in vitro--inhibition of 12-HPETE biosynthesis.

Authors:  H Darius; B Ahland; W Rücker; W Klaus; B A Peskar; K Schrör
Journal:  J Cardiovasc Pharmacol       Date:  1984 Jan-Feb       Impact factor: 3.105

9.  Experimental coronary artery occlusion. I. Measurement of infarct size.

Authors:  W Schaper; H Frenzel; W Hort
Journal:  Basic Res Cardiol       Date:  1979 Jan-Feb       Impact factor: 17.165

10.  Comparison of various methods for assessing infarct-size in the dog.

Authors:  P A Martorana; H Göbel; B Kettenbach; R E Nitz
Journal:  Basic Res Cardiol       Date:  1982 May-Jun       Impact factor: 17.165

View more
  1 in total

1.  Molsidomine on cardiovascular leukotriene D4 actions.

Authors:  V B Fiedler; T S Abram
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1985-04       Impact factor: 3.000

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.